NCT06613854 Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes
| NCT ID | NCT06613854 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University Medical Centre Ljubljana |
| Condition | Type 2 Diabetes Mellitus (T2DM) |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 90 participants in total. It began in 2024-10-01 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if early combination with two antidiabetic drugs further improves blood glucose control compared to a single drug regimen in adults with short duration of type 2 diabetes. It will also learn about the effect of the combination treatment on body weight, body composition, blood lipids, oxidative stress, inflammation, metabolic control, insulin resistance and insulin secretion from pancreas, together with its safety profile. The main questions it aims to answer are: * Does early combination with two antidiabetic drugs improve blood glucose levels, determined by continuous glucose monitoring system? * Is early combination treatment as safe as treatment with a single antidiabetic drug? * Does early combination treatment reduces the need for rescue therapy? * Does early combination treatment reduces body weight and improves body composition? * Does early combination treatment improves blood lipid parameters, oxidative stress and inflammation? * Does early combination treatment improves metabolic parameters? * Does early combination treatment improves insulin resistance and insulin secretion? Researchers will compare early combination treatment with metformin and either peroral semaglutide or empagliflozin to a single drug regimen with only metformin to see if the combination treatment works to treat type 2 diabetes. Participants will: * Take the combination of two antidiabetic drugs or only metformin for every day for 26 weeks. * Visit the clinic four times during the study duration for checkups and tests. * Carry a continuous glucose monitoring sensor for 14 days prior to study visits.
Eligibility Criteria
Inclusion Criteria: * Diagnosed with type 2 diabetes for up to 2 years (prior to randomization); * Aged between 18 and 70 years, both sexes, of any race or ethnicity; * HbA1c ≤8.0% at randomization; * Baseline treatment with metformin at a steady daily dose of ≥1500 mg; * Signed informed consent to participate in the study. Exclusion Criteria: * Treatment at any time in the past with SGLT2i, GLP-1RA, or DPP-4 inhibitors; * Insulin treatment for longer than 2 weeks in the past; * Body Mass Index below 22 kg/m2 or BMI above 40 kg/m2; * Chronic kidney disease stages 3-5 (eGFR below 60 ml/min or the presence of albuminuria (urine albumin-to-creatinine ratio above 34 g/mmol); * Known cardiovascular disease (angina pectoris, history of myocardial infarction, ischemic heart disease, heart failure, known carotid atherosclerosis, objectively proven peripheral arterial disease, or other known atherosclerotic disease at other locations); * Moderate or severe liver disease (Child-Pugh stage B or C); * Personal history of pancreatitis; * Advanced heart failure (NYHA III-IV); * Retinopathy or maculopathy or their active treatment; * Pregnancy, expected pregnancy, or breastfeeding; * Presence of active malignancy or personal history of malignancy within 5 years of study enrollment; * Personal history of thyroid cancer; personal or family history of multiple endocrine neoplasia type 2 or family history of medullary thyroid carcinoma; * Chronic inflammatory bowel disease; * History of bariatric surgery or other gastrointestinal surgery that could affect drug or nutrient absorption; * Frequent or severe urinary tract infections; * Presence of a urinary catheter; * Troublesome and recurrent genital fungal infections; * Personal history of ketoacidosis; * Symptomatic hypotension or predisposition to hypovolemia; * History of organ transplantation; * Allergy to any component in the semaglutide or empagliflozin oral tablet; * Any medical or social circumstance that may limit participation in the study (e.g., inability to attend regular study visits); * Any other condition that, in the opinion of the principal and responsible investigators, may affect the safety or efficacy of the treatment.
Frequently Asked Questions
Who can join the NCT06613854 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Type 2 Diabetes Mellitus (T2DM). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06613854 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06613854 currently recruiting?
Yes, NCT06613854 is actively recruiting participants. Visit ClinicalTrials.gov or contact University Medical Centre Ljubljana to inquire about joining.
Where is the NCT06613854 trial being conducted?
This trial is being conducted at Ljubljana, Slovenia.
Who is sponsoring the NCT06613854 clinical trial?
NCT06613854 is sponsored by University Medical Centre Ljubljana. The trial plans to enroll 90 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.